Logo image of RYZB

RAYZEBIO INC (RYZB) Stock Fundamental Analysis

NASDAQ:RYZB - Nasdaq - US75525N1072 - Common Stock - Currency: USD

62.49  +0.01 (+0.02%)

After market: 62.51 +0.02 (+0.03%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RYZB. RYZB was compared to 550 industry peers in the Biotechnology industry. While RYZB has a great health rating, there are worries on its profitability. RYZB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RYZB had negative earnings in the past year.
RYZB Yearly Net Income VS EBIT VS OCF VS FCFRYZB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -20M -40M -60M

1.2 Ratios

With an excellent Return On Assets value of -12.12%, RYZB belongs to the best of the industry, outperforming 87.42% of the companies in the same industry.
The Return On Equity of RYZB (-12.71%) is better than 89.60% of its industry peers.
Industry RankSector Rank
ROA -12.12%
ROE -12.71%
ROIC N/A
ROA(3y)-17.78%
ROA(5y)N/A
ROE(3y)-18.96%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RYZB Yearly ROA, ROE, ROICRYZB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 -5 -10 -15 -20 -25

1.3 Margins

RYZB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RYZB Yearly Profit, Operating, Gross MarginsRYZB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022

More info and screens

9

2. Health

2.1 Basic Checks

The number of shares outstanding for RYZB remains at a similar level compared to 1 year ago.
There is no outstanding debt for RYZB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RYZB Yearly Shares OutstandingRYZB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 10M 20M 30M 40M 50M
RYZB Yearly Total Debt VS Total AssetsRYZB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 100M 200M 300M

2.2 Solvency

RYZB has an Altman-Z score of 81.41. This indicates that RYZB is financially healthy and has little risk of bankruptcy at the moment.
RYZB has a Altman-Z score of 81.41. This is amongst the best in the industry. RYZB outperforms 98.32% of its industry peers.
RYZB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 81.41
ROIC/WACCN/A
WACCN/A
RYZB Yearly LT Debt VS Equity VS FCFRYZB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 31.85 indicates that RYZB has no problem at all paying its short term obligations.
RYZB has a Current ratio of 31.85. This is amongst the best in the industry. RYZB outperforms 98.66% of its industry peers.
RYZB has a Quick Ratio of 31.85. This indicates that RYZB is financially healthy and has no problem in meeting its short term obligations.
RYZB has a Quick ratio of 31.85. This is amongst the best in the industry. RYZB outperforms 98.66% of its industry peers.
Industry RankSector Rank
Current Ratio 31.85
Quick Ratio 31.85
RYZB Yearly Current Assets VS Current LiabilitesRYZB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for RYZB have decreased strongly by -29.41% in the last year.
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RYZB will show a decrease in Earnings Per Share. The EPS will decrease by -7.55% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-152.17%
EPS Next 2Y-11.77%
EPS Next 3Y-7.55%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RYZB Yearly EPS VS EstimatesRYZB Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RYZB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RYZB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RYZB Price Earnings VS Forward Price EarningsRYZB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RYZB Per share dataRYZB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

RYZB's earnings are expected to decrease with -7.55% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.77%
EPS Next 3Y-7.55%

More info and screens

0

5. Dividend

5.1 Amount

RYZB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAYZEBIO INC

NASDAQ:RYZB (2/23/2024, 8:10:27 PM)

After market: 62.51 +0.02 (+0.03%)

62.49

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/amc
Earnings (Next)N/A N/A
Inst Owners0.06%
Inst Owner Change0%
Ins Owners11%
Ins Owner Change0%
Market Cap3.81B
Analysts80
Price Target54.4 (-12.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)70.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.03%
EPS NY rev (1m)0%
EPS NY rev (3m)-28.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.63
P/tB 6.63
EV/EBITDA N/A
EPS(TTM)-1.32
EYN/A
EPS(NY)-1.65
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS9.43
TBVpS9.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.12%
ROE -12.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.78%
ROA(5y)N/A
ROE(3y)-18.96%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 31.85
Quick Ratio 31.85
Altman-Z 81.41
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)2137.39%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-152.17%
EPS Next 2Y-11.77%
EPS Next 3Y-7.55%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-83.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.39%
EBIT Next 3Y-32.91%
EBIT Next 5YN/A
FCF growth 1Y-65.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.01%
OCF growth 3YN/A
OCF growth 5YN/A